Doylestown, PA

Doylestown Health Cardiology

Atrial Fibrillation

Myocardial Ischemia

Coronary Artery Disease

Heart Diseases

Heart Failure

Coronary Disease

Myocardial Infarction

Pulmonary Arterial Hypertension

Type 2 Diabetes Mellitus

Ischemia

EMPagliflozin

Evolocumab

Medication

Linagliptin

Empagliflozin

Boehringer Ingelheim

Amgen

Medtronic

Actelion Pharmaceuticals

Duke University

NYU Langone Health

condition

Infarction

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Doylestown Health Cardiology | Doylestown, PA

Site insights

Work at this site?

Active trials

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Trial sponsors